Year All2024202320222021202020192018201720162015201420132012201120102007 06.13.19 Syndax to Present at the JMP Securities Life Sciences Conference WALTHAM, Mass. , June 13, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Read More 05.14.19 Syndax to Present at the UBS Global Healthcare Conference WALTHAM, Mass. , May 14, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More 05.06.19 Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update - E2112 trial passes fourth interim analysis for OS; trial to continue, with next preplanned analysis expected in 4Q19 - - IND filing for targeted menin inhibitor SNDX-5613 on track for 2Q19 - - Company to host conference call today at 4:30 p.m. ET - WALTHAM, Mass. Read More 04.29.19 Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019 WALTHAM, Mass. , April 29, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2019 financial Read More 04.01.19 Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting - 19% objective response rate and 36% clinical benefit rate, with 13-month median duration of response in melanoma patients whose disease progressed on or after anti-PD-1 therapy - - Gene expression analyses provide mechanistic insight for enhanced clinical benefit observed in biomarker-defined Read More 03.27.19 Syndax Announces $26.2 Million Offering of Common Stock and Warrants WALTHAM, Mass. , March 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with Biotechnology Value Read More 03.07.19 Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update - Next interim OS assessment for Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected in 2Q19 - - IND filing for targeted therapy SNDX-5613, the Company's Menin inhibitor, expected in 2Q19 - - Company to host conference call today at 4:30 p.m. ET - WALTHAM, Mass. Read More 03.06.19 Syndax to Present at the Cowen 39th Annual Health Care Conference WALTHAM, Mass. , March 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More 02.28.19 Syndax to Announce Fourth Quarter and Year-end 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019 WALTHAM, Mass. , Feb. 28, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter 2018 financial Read More 02.27.19 Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019 WALTHAM, Mass. , Feb. 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced two oral presentations at the upcoming American Association Read More 01.07.19 Syndax Highlights 2019 Clinical and Corporate Outlook - Data from ENCORE I/O combination program in melanoma and ovarian cancer expected in 1Q19, TNBC in 2Q19 - - Next interim OS assessment in Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected in 2Q19 - - IND filing for lead Menin-MLLr inhibitor, SNDX-5613, expected in 2Q19 - WALTHAM, Read More 12.03.18 Syndax Pharmaceuticals Announces Presentation of Preclinical Data from Menin-MLL Program at the 60th American Society of Hematology Annual Meeting - Preclinical data provide further support for the clinical application of Company's Menin-MLL program in acute leukemias - WALTHAM, Mass. , Dec. 3, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company Read More
06.13.19 Syndax to Present at the JMP Securities Life Sciences Conference WALTHAM, Mass. , June 13, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Read More
05.14.19 Syndax to Present at the UBS Global Healthcare Conference WALTHAM, Mass. , May 14, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More
05.06.19 Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update - E2112 trial passes fourth interim analysis for OS; trial to continue, with next preplanned analysis expected in 4Q19 - - IND filing for targeted menin inhibitor SNDX-5613 on track for 2Q19 - - Company to host conference call today at 4:30 p.m. ET - WALTHAM, Mass. Read More
04.29.19 Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019 WALTHAM, Mass. , April 29, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2019 financial Read More
04.01.19 Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting - 19% objective response rate and 36% clinical benefit rate, with 13-month median duration of response in melanoma patients whose disease progressed on or after anti-PD-1 therapy - - Gene expression analyses provide mechanistic insight for enhanced clinical benefit observed in biomarker-defined Read More
03.27.19 Syndax Announces $26.2 Million Offering of Common Stock and Warrants WALTHAM, Mass. , March 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with Biotechnology Value Read More
03.07.19 Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update - Next interim OS assessment for Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected in 2Q19 - - IND filing for targeted therapy SNDX-5613, the Company's Menin inhibitor, expected in 2Q19 - - Company to host conference call today at 4:30 p.m. ET - WALTHAM, Mass. Read More
03.06.19 Syndax to Present at the Cowen 39th Annual Health Care Conference WALTHAM, Mass. , March 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More
02.28.19 Syndax to Announce Fourth Quarter and Year-end 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019 WALTHAM, Mass. , Feb. 28, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter 2018 financial Read More
02.27.19 Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019 WALTHAM, Mass. , Feb. 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced two oral presentations at the upcoming American Association Read More
01.07.19 Syndax Highlights 2019 Clinical and Corporate Outlook - Data from ENCORE I/O combination program in melanoma and ovarian cancer expected in 1Q19, TNBC in 2Q19 - - Next interim OS assessment in Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected in 2Q19 - - IND filing for lead Menin-MLLr inhibitor, SNDX-5613, expected in 2Q19 - WALTHAM, Read More
12.03.18 Syndax Pharmaceuticals Announces Presentation of Preclinical Data from Menin-MLL Program at the 60th American Society of Hematology Annual Meeting - Preclinical data provide further support for the clinical application of Company's Menin-MLL program in acute leukemias - WALTHAM, Mass. , Dec. 3, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company Read More